Download PDF WhiMSICAL Study
Waldenström’s Macroglobulinemia Study Involving CART-WHEEL
A world-first, ethically-approved, comprehensive global database
of patient-derived data about your WM experience
Join WhiMSICAL to “pay it forward” and help WM patients around the… Continue reading
If you were not able to attend the workshop on 4 October 2017, “What’s New in the Treatment of Waldenstrom’s Macroglobulinemia (WM),” it is available online via webcast here (link is external) or on telephone replay… Continue reading
BGB-3111 is a potent and highly selective small molecule BTK inhibitor (Bruton’s Tyrosine Kinase), which we are developing as a monotherapy and in combination with other therapies for the treatment of a variety of lymphomas—the most common form of blood… Continue reading
Judith Trotman, MD, clinical associate professor, medicine, Concord Clinical School, The University of Sydney, discusses results of a trial investigating BGB-3111 in patients with Waldenstrom’s macroglobulinemia (WM).
BGB-3111 is a very specific BTK inhibitor that has a very high, very… Continue reading
Download article here: Cryoglobulinemia
Cryoglobulinemia: Causes, symptoms, and treatment
Last reviewed Mon 31 July 2017
By Jenna Fletcher
Reviewed by Judith Marcin, MD
Cryoglobulinemia may only appear in cold weather.
Cryoglobulinemia is a disease caused by an abundance… Continue reading
Sunesis Pharmaceuticals Announces First Patient Dosed in Phase 1b:2 Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 in Adults with Chronic Lymphocytic Leukemia and other B-Cell Malignancies Nasdaq:SNSS
July 18, 2017 16:05 ET | Source: Sunesis Pharmaceuticals Inc
SOUTH SAN FRANCISCO, Calif.,… Continue reading
WMFC Members, we received the following update on the WhiMSICAL program. Your participation is highly encouraged. Thank you for the support!
Waldendstom’s Macroglobulinemia Study Involving CArt-WheeL
a world-first, ethically-approved, comprehensive survey of patient –… Continue reading